Down 30%, Worth a Look

XOMA falls after phase 2 trials fail, but its anti-inflammatory drug gevokizumab still has potential in other diseases.

Mar 6, 2014 at 9:32PM

It's never a good sign when the first paragraph of a press release announcing clinical trial results for one disease starts talking about the other trials where the drug is being tested. Investors didn't buy the smokescreen XOMA (NASDAQ:XOMA) put up on Tuesday when it announced the results of the phase 2 trials testing gevokizumab in patients with erosive osteoarthritis of the hand, or EOA. Shares ended Wednesday down 28% and it's fell a little more today.

While XOMA is still testing gevokizumab in multiple indications, the loss of EOA is a big blow given the market potential for the disease. The failure could also be a sign that gevokizumab isn't as active as XOMA and investors have hoped, although I think that negative view might be a bit of a stretch.

In one of the phase 2 studies, gevokizumab seemed to be performing well after 84 days of treatment, but then, in the latter half of the trial, the placebo group improved, negating the difference seen in the first half. By day 168, the difference wasn't statistically significant.

This type of placebo effect -- patients getting placebo shouldn't improve -- is all too common for diseases where patients report how they're feeling. For example, in one of Pfizer's (NYSE:PFE) trials of Xeljanz, its rheumatoid arthritis drug, 27% of patients reported a 20% improvement in their symptoms despite having taken nothing that should help their disease. Pfizer was still able to show statistical significance because Xeljanz works so well, but not every rheumatoid arthritis drug has been so lucky.

Glimmer of hope
When XOMA looked at patients with more severe disease, the placebo group didn't fair nearly as well, which supports the placebo effect hypothesis; it's harder to trick your mind into thinking you've improved when you're in severe pain.

Fortunately, the company doesn't seem to be latching onto the subset of data. XOMA has decided not to move gevokizumab into a phase 3 program in a broad EOA indication, and seems to be downplaying the potential in severe EOA in the press release: "It is possible these observations, as well as further analyses, could provide a reasonable group to study in future trials but it is too early to tell at this point."

"Possible," "could," "too early," all sound good to me, given that XOMA is older than dirt (in biotech years), having produced failed idea after failed idea and a few not-so-profitable successes. XOMA doesn't need to be taking any long shots at this point.

Other opportunities
While the decline in XOMA's stock price is deserved given the decrease in sales potential if the company isn't going to pursue EOA, gevokizumab is far from dead. It's shown pretty good phase 2 results in two different indications.

Phase 3 trials in two related eye diseases, Behcet's uveitis and non-infectious uveitis, have already begun. The trial for Behcet's uveitis, run by XOMA's partner Servier, should read out in the middle of this year. Enrollment in the two trials for non-infectious uveitis has been slower than expected, but XOMA will have data eventually.

For pyoderma gangrenosum, a rare inflammatory skin disease, XOMA is scheduled to have an end-of-phase-2 meeting with the FDA to help design a pivotal trial. Given the unmet need, a single phase 3 trial should be sufficient to gain approval. And there's potential for gevokizumab to work in other inflammatory diseases, such as severe acne, autoimmune inner ear disease, and other diseases that are mediated by interleukin-1 beta, which gevokizumab inhibits.

At a market cap of $600 million, XOMA looks like a decent orphan drug company investment for investors willing to hold for a few years.

Growth beyond biotech
Finding hyper-growth is a matter of identifying trends before they happen. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play," and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers